We make way more than that and deserve every penny. We are identifying patients who have no other options for treatments. It’s not an easy job, I work very hard, and it’s the most challenging job, but most money I’ve ever made in my life. I love it here.
This is the biggest bunch of crap statement ever! I sold this drug - you are an alternative for steroids - patients are having a relapse - you work hard, what a bunch of crap. It's a 60 year old drug that is priced way out of line. Keep telling yourself you work hard, because no one else will. New treatments will make your job "harder" - so I guess you will be working even harder.
Yoy deserve to make “way more” than 300k???? Lolol - You need a reality check. When u get shut down, you’ll be in the mid 20k range where you belong!
I hope SEC is reading this thread. To comment on the debt split, from an accounting standpoint they are limited to loading the gx (MNK) unit with debt that was used directly to finance that unit which now includes ~1 B that was used to finance Sucampo which was one of the most well known dogs in the the industry. No one would ever have bought that pile of rubbish (one of the worst pipelines out there), but never underestimate the desperation of the CEO to have something to distract board members and investors to save his job. No one bought the PR distraction spin and the stock tanked appropriately over time. At least 4.5-5 B of the debt will be associated with all the "branded" assets that were borrowed to finance a string of winners including Ofirmev, Acthar, Inomax, Therakos etc....If they try to do anything else, the SEC needs to investigate (they actually should investigate regardless since there are other past shenanigans that MH and his army of accountants and treasurers have been up to to cook the books to make it look like certain parts of the business were profitable but were in the red for the past 3 years...gx...)...both units may head to bankruptcy! That would be legendary.
As a former Depomed “boots on the ground” representative who successfully promoted Gralise, Cambia, Zipsor portfolio, it baffles me the bean counters replies. The products are great, the issue is most patients are on Medicare/Medicaid, of which all are barely covered for patient access. Luckily, the sales force was dealt a favor of a National lay-off early last year. Even with all these cost savings, Purdue settlement, NDA for Cosyntropin, the stock is still tanking fast. The CEO is not being held accountable for any of this even after Starboard has sold most of their holdings. Lots of questions remain for the future of the company.
